With more ADCs and bioconjugates entering late-stage development, demand for commercial-scale manufacturing is rising. Commercializing ADCs and bioconjugates requires interdisciplinary expertise spanning both biologics and small-molecule development—expertise that individual biopharmaceutical companies may not always possess. These challenges, combined with accelerated development timelines, increase the complexity of ADC and bioconjugate development and commercial manufacturing.
In this webinar, we will discuss strategies to address these challenges and to enable high-quality ADC and bioconjugate manufacturing. We will also introduce WuXi XDC Singapore site and our Global Dual-Sourcing strategy — to further support the growth of the ADC and bioconjugates to enable the success of our partners worldwide.
Key Learning Objectives
- Challenges and Key Considerations in ADC & Bioconjugate Manufacturing
- Integrated Solutions to Overcome the Challenges
- The Cornerstone of Global Dual-Sourcing Strategy: WuXi XDC Singapore Site
- Benchmark cases of Partner Empowerment